GlassScriptPhysician profile
Aditya Hendrani
NPI 1295176113
$1,687.31
in general payments reported to CMS, 2019-2025
15 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $170 · 2021: $224 · 2022: $413 · 2023: $86.51 · 2024: $350 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $385.03 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.76 | 2019-2025 | Lifevest |
| Abbott Laboratories | $157.67 | 2022-2024 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.57 | 2021-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $122.17 | 2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $92.39 | 2019-2024 | Dupixent |
| Abiomed | $80.56 | 2020 | |
| Impulse Dynamics (USA) INC. | $76.96 | 2022-2023 | Optimizer |
| Atricure, INC. | $66.53 | 2019 | |
| Amgen INC. | $64.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $64.29 | 2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $62.32 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $44.52 | 2025 | Onpattro, Amvuttra |
| Scpharmaceuticals INC. | $20.85 | 2025 | |
| Bridgebio Pharma, INC. | $20.05 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Hendrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.